IGM Financial Inc. (TSE:IGM – Get Free Report) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of C$43.75 and traded as high as C$43 ...

IGM Biosciences (NASDAQ:IGMS) is slashing its workforce by 73% and discontinuing development of two of its lead drug candidates, imvotamab and IGM-2644, in the wake of disappointing data.

IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% ...

With the Canadian market facing uncertainties due to potential tariffs and political shifts, investors are increasingly adopting a defensive stance. In this environment, dividend stocks can offer a ...

The tech sector's revenue and earnings growth rates are projected to accelerate in 2025. IGM's diversified portfolio, including mega, large, mid, and small caps, offers broad tech exposure ...

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on IGM Biosciences (IGMS – Research Report), with a ...

In a report released today, Michael Ulz from Morgan Stanley maintained a Sell rating on IGM Biosciences (IGMS – Research Report), with a price ...

High antibody titers of anti–citrullinated peptide antibodies, rheumatoid factor, and certain baseline factors predict RA ...

If you wish to manage your notification settings from this browser you will need to update your browser's settings for this site. Just click button below and allow notifications for this site Note ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...